Genomma Lab Internacional Announces Long-Term Debt Transaction

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international reach, announces that it has entered into a new MXN $1.0 billion long-term credit facility with Banamex, with a 3-year term. The proceeds from this credit facility will be primarily used to refinance and prepay the Company's financial liabilities, including the repayment of an existing bank loan and upcoming maturities of the Company's outstanding certificates. Antonio Zamora Galland, CFO, commented: "We appreciate Banamex's support through this long-term financing, which is part of Genomma Lab's strategy to optimize its debt maturity profile, strengthen the management of its working capital structure, and maintain a solid financial position that supports the growth of the business." Jorge Rohana de la Vega, Corporate Director at Banamex, commented: "We are pleased to support Genomma Lab. This credit facility is part of our commitment to driving the growth of our clients and our strategy of being a partner to Mexican companies across all regions and sectors. In this way, we contribute to Mexico's economic development." Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com